Niagen Bioscience Yönetim
Yönetim kriter kontrolleri 2/4
Niagen Bioscience CEO'su Rob Fried, Jun2018 tarihinde atandı, in görev süresi 8.08 yıldır. in toplam yıllık tazminatı $ 8.38M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.7% maaş ve 92.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.09% ine doğrudan sahiptir ve bu hisseler $ 5.72M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.4 yıl ve 9.2 yıldır.
Anahtar bilgiler
Rob Fried
İcra Kurulu Başkanı
US$8.4m
Toplam tazminat
| CEO maaş yüzdesi | 7.71% |
| CEO görev süresi | 8.1yrs |
| CEO sahipliği | 2.1% |
| Yönetim ortalama görev süresi | 6.4yrs |
| Yönetim Kurulu ortalama görev süresi | 9.2yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 30
NAGE: Future Execution On Telehealth Platform Will Drive Upside Potential
Niagen Bioscience's analyst price target has been revised lower from $23.00 to $18.00 as analysts incorporate updated assumptions for revenue growth, profit margin, discount rate, and future P/E into their models. Analyst Commentary Bullish analysts following Niagen Bioscience are revisiting their models at a detailed level, adjusting assumptions for revenue growth, profit margins, discount rates, and future P/E multiples.
Anlatı Güncellemesi • Jun 16
NAGE: Injectables And Expanded Clinical Access Will Support Future Buyback Upside
Niagen Bioscience's analyst price target has been reduced by a combined $5 across recent reports as analysts factor in updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples, while maintaining a fair value estimate of $12.60. Analyst Commentary Recent research on Niagen Bioscience highlights a mix of optimism about the company’s long term potential and caution around the assumptions that underpin the current fair value estimate of $12.60.Anlatı Güncellemesi • Jun 02
NAGE: Core Demand And Injectables Will Support Future Buyback Driven Upside
Analysts have trimmed their average price target on Niagen Bioscience by $1 to $12.60, reflecting updated models that incorporate modest adjustments to discount rates, revenue growth, profit margin assumptions, and a slightly lower future P/E multiple. Analyst Commentary Recent Street research around Niagen Bioscience centers on how updated models reconcile the current share price with revised assumptions for growth, profitability, and valuation multiples.Anlatı Güncellemesi • May 14
NAGE: Core Demand And Injectables Will Drive Future Upside Potential
Niagen Bioscience's analyst price target has shifted from $13.60 to $12.60, as analysts adjust their models to slightly lower revenue growth, profit margin, and fair value assumptions while still highlighting ongoing demand in the core business and potential upside from the injectable segment. Analyst Commentary Recent research updates show a consistent pattern of price target reductions, with the latest move taking the blended target to US$12.60.Anlatı Güncellemesi • Apr 22
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that point to steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Recent commentary around Niagen Bioscience centers on how updated Q4 models affect the risk and reward trade off, with attention on both the established core business and the injectable opportunity.Anlatı Güncellemesi • Apr 07
NAGE: Core Strength And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that reflect steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Analysts see the updated price target as largely reflecting model clean up after Q4, rather than a shift in the overall view on the business.Anlatı Güncellemesi • Mar 23
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14. This reflects updated models after Q4 results that pointed to steady demand in the core business and potential upside from the injectable segment.Anlatı Güncellemesi • Mar 06
NAGE: Core Demand And Injectables Outlook Will Support Future Upside
Analysts have trimmed their 12 month price target on Niagen Bioscience from $16.04 to $13.60, citing updated models that reflect steady demand in the core business, potential upside in injectables, adjustments to revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to steady demand in the core business as a key support for current valuation, suggesting the updated models still see the existing portfolio as a meaningful earnings driver.Seeking Alpha • Nov 15
Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years
Summary Niagen Bioscience delivered record Q3 revenue, rising 33% year-over-year, driven by strong Tru Niagen demand and accelerating distribution partnerships. Gross margin expanded to 64.5%, while operating income and adjusted EBITDA grew sharply, reflecting improving scale and cost discipline. Cash from operations already exceeded last year’s total, supporting a new $10 million share repurchase program. The FDA’s reversal on NMN introduces meaningful uncertainty for future demand and competitive dynamics in the NAD+ category. Niagen Bioscience remains financially strong, but sustained momentum in a post-NMN market is unproven, warranting a hold rating. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 11
We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve
Even though Niagen Bioscience, Inc. ( NASDAQ:NAGE ) posted strong earnings, investors appeared to be underwhelmed. We...Analiz Makalesi • Nov 07
Niagen Bioscience, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) just released its quarterly report and things are looking bullish. The company...Analiz Makalesi • Oct 03
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues
To the annoyance of some shareholders, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares are down a considerable 25% in...Anlatı Güncellemesi • Aug 08
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
Upward revisions to Niagen Bioscience's price target reflect positive clinical trial results confirming both safety and significant efficacy of its NAD+ supplementation, increased market confidence, and ongoing product and sales momentum, resulting in a higher consensus analyst price target rising from $14.90 to $15.84. Analyst Commentary Positive clinical study results published in a peer-reviewed journal demonstrated that Niagen Bioscience’s NAD+ supplementation is safe for patients with Werner syndrome and achieved a ~140% increase in blood NAD+ levels, along with improvements in liver, kidney, and arterial health markers.Analiz Makalesi • Aug 08
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Analiz Makalesi • Aug 06
What You Can Learn From Niagen Bioscience, Inc.'s (NASDAQ:NAGE) P/S After Its 28% Share Price Crash
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Analiz Makalesi • Jun 17
Market Participants Recognise Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Revenues Pushing Shares 29% Higher
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares have continued their recent momentum with a 29% gain in the last month...Analiz Makalesi • May 10
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
A week ago, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) came out with a strong set of first-quarter numbers that could...Analiz Makalesi • Apr 05
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues
The Niagen Bioscience, Inc. ( NASDAQ:NAGE ) share price has softened a substantial 30% over the previous 30 days...Analiz Makalesi • Mar 29
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE)
Key Insights Niagen Bioscience's estimated fair value is US$7.18 based on 2 Stage Free Cash Flow to Equity Niagen...
Yeni Anlatı • Feb 09
NIAGEN IV Expansion And FDA Approvals Will Unlock Future Opportunities
Expansion in clinics and strategic partnerships support revenue growth through increased e-commerce and pharmaceutical-grade product sales.Analiz Makalesi • Nov 07
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
ChromaDex Corporation's ( NASDAQ:CDXC ) strong earnings report was rewarded with a positive stock price move. We did...Analiz Makalesi • Nov 05
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Despite an already strong run, ChromaDex Corporation ( NASDAQ:CDXC ) shares have been powering on, with a gain of 70...Analiz Makalesi • Jul 25
ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company
Those holding ChromaDex Corporation ( NASDAQ:CDXC ) shares would be relieved that the share price has rebounded 25% in...Analiz Makalesi • Jun 15
Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable
Key Insights ChromaDex's Annual General Meeting to take place on 20th of June Total pay for CEO Rob Fried includes...Analiz Makalesi • Jun 05
Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump
ChromaDex Corporation ( NASDAQ:CDXC ) shares have retraced a considerable 26% in the last month, reversing a fair...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$19m |
| Dec 31 2025 | US$8m | US$646k | US$17m |
| Sep 30 2025 | n/a | n/a | US$20m |
| Jun 30 2025 | n/a | n/a | US$18m |
| Mar 31 2025 | n/a | n/a | US$14m |
| Dec 31 2024 | US$1m | US$500k | US$9m |
| Sep 30 2024 | n/a | n/a | US$1m |
| Jun 30 2024 | n/a | n/a | -US$1m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$1m | US$500k | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$6m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$1m | US$500k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$20m |
| Jun 30 2022 | n/a | n/a | -US$28m |
| Mar 31 2022 | n/a | n/a | -US$27m |
| Dec 31 2021 | US$1m | US$500k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | US$1m | US$519k | -US$20m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$30m |
| Dec 31 2019 | US$2m | US$487k | -US$32m |
Tazminat ve Piyasa: Rob 'nin toplam tazminatı ($USD 8.38M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.64M ).
Tazminat ve Kazançlar: Rob 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Rob Fried (66 yo)
8.1yrs
Görev süresi
US$8,381,900
Tazminat
Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of Niagen Bioscience, Inc. (formerly known as ChromaDex Corporation) since June 22, 2018 and its a Director since July 2015. Mr....
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Chairman | 26.4yrs | US$268.08k | 2.91% $ 8.0m | |
| CEO & Director | 8.1yrs | US$8.38m | 2.09% $ 5.7m | |
| CFO & Principal Accounting Officer | 1.8yrs | US$648.24k | 0.012% $ 32.9k | |
| Senior VP & General Counsel | 2yrs | US$558.01k | 0.0028% $ 7.7k | |
| Senior Vice President of Global Regulatory & Scientific Affairs | 6.4yrs | Veri yok | Veri yok | |
| Chief Marketing Officer | 1.7yrs | Veri yok | Veri yok | |
| Managing Director of Asia Pacific | 7.8yrs | Veri yok | Veri yok | |
| Head of Media Relations & Partnerships | no data | Veri yok | Veri yok | |
| Controller | no data | US$374.47k | 0% $ 0 | |
| Vice President of Finance | no data | Veri yok | Veri yok | |
| Assistant Controller | no data | Veri yok | Veri yok |
6.4yrs
Ortalama Görev Süresi
50yo
Ortalama Yaş
Deneyimli Yönetim: NAGE 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.4 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Chairman | 26.4yrs | US$268.08k | 2.91% $ 8.0m | |
| CEO & Director | 11yrs | US$8.38m | 2.09% $ 5.7m | |
| Member of Scientific Advisory Board | 9.1yrs | Veri yok | Veri yok | |
| Lead Independent Director | 9.3yrs | US$293.08k | 0.0088% $ 24.0k | |
| Chairman of the Scientific Advisory Board | 12yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 11.8yrs | Veri yok | Veri yok | |
| Independent Director | 4.3yrs | US$265.58k | 0% $ 0 | |
| Non-Executive Director | 8.9yrs | US$243.08k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$258.08k | 0% $ 0 | |
| Chief Scientific Advisor & Member of Scientific Advisory Board | 11.8yrs | Veri yok | Veri yok | |
| Member of the Scientific Advisory Board | 7yrs | Veri yok | Veri yok | |
| Non-Executive Director | 4.6yrs | US$245.58k | 0% $ 0 |
9.2yrs
Ortalama Görev Süresi
65yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: NAGE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.2 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/06 11:55 |
| Gün Sonu Hisse Fiyatı | 2026/07/02 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Niagen Bioscience, Inc. 8 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |
| Jeffrey Mark | Farmhouse Equity Research |